Low-Abundance Proteomics Reveal Pleiotrophin and Fibroblast Growth Factor-21 as Biomarkers of Metabolic Dysfunction-Associated Steatohepatitis.

ABSTRACT: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to comorbidities like obesity, type 2 diabetes, and cardiovascular disease. Given that liver biopsy is the diagnostic gold standard, there is a critical need for minimally invasive tests, particularly for the inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH). In this discovery study, we investigated the plasma proteome to identify blood biomarkers for MASH and explored their potential tissue sources, the liver and visceral adipose tissue. Plasma low-abundance proteome profiling was performed on samples from a cohort of morbidly obese MASLD subjects (n = 90; 40 with MASH, 50 without) using Olink^® panels. Paired liver and visceral adipose biopsies were also analyzed. Data sh

SUBMITTER: Milito MM 

PROVIDER: S-EPMC12652421 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature